Zeldes Haeggquist & Eck, LLP Announces Investigation of Chemed Corp.

Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation into Chemed Corp. (NYSE: CHE), (“Chemed” or the “Company”) to determine whether the Company’s Officers and Directors have breached their fiduciary duties owed to the Company and its shareholders.

Chemed is a company that owns and operates hospice units through its subsidiary Vitas.  On May 2, 2013, the U.S. Department of Justice (the “DOJ”) filed a lawsuit which alleges that Chemed and Vitas knowingly submitted claims to Medicare for reimbursement for services that were not necessary, not performed, or were not performed in compliance with Medicare guidelines in violation of the False Claims Act.  The DOJ’s complaint alleges that Chemed’s false claims to Medicare cost U.S. taxpayers tens of millions of dollars.  When the news of the DOJ’s lawsuit became public, Chemed’s stock price dropped dramatically, erasing millions of dollars of shareholder equity.  We are investigating whether the Officers and Directors of Chemed breached their fiduciary duties owed to the Company and its shareholders by allowing or failing to prevent the actions which gave rise to the DOJ’s lawsuit.

If you are a long term Chemed shareholder, you may have legal claims against Chemed’s Officers and Directors. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber L. Eck at (619) 342-8000, or by email at ambere@zhlaw.com. There is no cost to you.